ResMed (RMD) Stock Falls After Sleep Apnea Treatment Misses Primary Endpoint in Phase III Trial

NEW YORK (TheStreet) -- Shares of ResMed  (RMD) fell 15.02% to $55.55 in late morning trading Wednesday after the sleep disorder treatment manufacturer provided an update on its Phase III study of SERVE-HF, an adaptive servo-ventilation (ASV) therapy, in central sleep apnea and chronic heart failure.

The company announced that SERVE-HF did not meet its primary endpoint in the study. ResMed designed the study to assess if treatment of moderate to severe predominant central sleep apnea with ASV therapy could reduce mortality and morbidity in patients with symptomatic chronic heart failure in addition to optimized medical care.

The preliminary data did not indicate a statistically significant difference between patients randomized to ASV therapy and those in the control group in the primary endpoint of time to all-cause mortality or unplanned hospitalization for worsening heart failure.

More than 6 million shares had changed hands as of 11:39 a.m., compared to the daily average volume of 826,749.

RMD ChartRMD data by YCharts

If you liked this article you might like

Markets Take the Government Shutdown in Their Stride: Market Recon

Markets Take the Government Shutdown in Their Stride: Market Recon

How to Play Eight Potential Breakout Stocks

How to Play Eight Potential Breakout Stocks

Here's Why This Rally Is Sustainable: Cramer's 'Mad Money' Recap (Tuesday 1/24/17)

Here's Why This Rally Is Sustainable: Cramer's 'Mad Money' Recap (Tuesday 1/24/17)

ResMed: Cramer's Top Takeaways

ResMed: Cramer's Top Takeaways

Why CarMax and Garmin Could Be Prime Candidates for a Short Squeeze

Why CarMax and Garmin Could Be Prime Candidates for a Short Squeeze